EUVIMEDEUVIMED entdecken
Crossref

Targeted Therapy for CD13‐Overexpressing Triple‐Negative Breast Cancers Using Apoptosis‐Inducing Protein Cage Nanoparticles

Heejin Jun, Junsu Kim, Soomin Eom, Diane Jeong, Sebyung Kang iD

Macromolecular Bioscience · 2026

DOI: 10.1002/mabi.202500645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Macromolecular Bioscience, 2026. Verfasst von Heejin Jun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, CD13 Antigens, Nanoparticles, TNF-Related Apoptosis-Inducing Ligand. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes to treat due to the lack of well‐defined molecular targets. Cluster of differentiation 13 (CD13), a cell surface aminopeptidase, is highly expressed in various tumors and play critical roles in promoting angiogenesis, aberrant proliferation, invasion, and metastasis. In this study, we investigated CD13 as a potential therapeutic target in TNBC cell lines to enable targeted therapy. Accordingly, we employed a protein cage nanoparticle, AaLS/TRAIL/aCD13Nb, which simultaneously displays CD13‐binding nanobodies (aCD13Nb) and tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) via the SpyCatcher/SpyTag protein ligation system. This dual‐ligand nanoparticle exhibited enhanced and specific binding to CD13‐overexpressing TNBC cell lines, including HCC1937, MDA‐MB‐468, and BT‐549 cells. aCD13Nb‐mediated tight binding facilitated sustained interaction of TRAIL with death receptors, resulting in robust activation of apoptotic signaling cascades and significantly enhanced therapeutic efficacy in CD13‐overexpressing TNBC cell lines. Moreover, systemic administration of AaLS/TRAIL/aCD13Nb via intravenous injection markedly suppressed tumor growth in an HCC1937 xenograft mouse model, without evidence of systemic toxicity. These findings validate CD13 as a promising therapeutic target in TNBC and underscore the potential of dual‐ligand protein cage nanoparticles as an effective platform for targeted cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCD13 AntigensNanoparticlesTNF-Related Apoptosis-Inducing LigandApoptosisMolecular Targeted TherapyHumansFemaleAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysMice, Nude

Stichwörter der Autor:innen

CD13TRAILlumazine synthaseprotein cage nanoparticlestriple negative breast cancer

Substanzen

CD13 AntigensTNF-Related Apoptosis-Inducing Ligand

Autor:innen und Institutionen

  • Department of Biological Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea.

ORCID-Profile: Sebyung Kang

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Jun, H., Kim, J., Eom, S., Jeong, D., & Kang, S. (2026). Targeted Therapy for CD13‐Overexpressing Triple‐Negative Breast Cancers Using Apoptosis‐Inducing Protein Cage Nanoparticles. Macromolecular Bioscience. https://doi.org/10.1002/mabi.202500645

Vancouver

Jun H, Kim J, Eom S, Jeong D, Kang S. Targeted Therapy for CD13‐Overexpressing Triple‐Negative Breast Cancers Using Apoptosis‐Inducing Protein Cage Nanoparticles. Macromolecular Bioscience. 2026. doi:10.1002/mabi.202500645

BibTeX
@article{Jun2026,
  author = {Jun, Heejin and Kim, Junsu and Eom, Soomin and Jeong, Diane and Kang, Sebyung},
  title = {Targeted Therapy for CD13‐Overexpressing Triple‐Negative Breast Cancers Using Apoptosis‐Inducing Protein Cage Nanoparticles},
  journal = {Macromolecular Bioscience},
  year = {2026},
  doi = {10.1002/mabi.202500645}
}
Kostenlos starten →